Created On: 2020-07-15
Record Count: 9
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 280951
BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.
IPSCIO Record ID: 256328
IPSCIO Record ID: 28678
The University is the owner of certain Patent Rights (as later defined in this Agreement) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed: June 7, 1995).
Patent Rights means all of the following UA intellectual property:
(a) the US Patent application No. 08/480,499 A Method for Eliciting a Thl Specific Immune Response (filed: June 7, 1995);
(b) the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), a continuation-in-part of 1.6 (a) and later issued as US Patent No. 6,168,804 (issued: January 2, 2001);
(c) the US Patent application No. 09/668,825 A Method for Eliciting a Thl Specific Immune Response, a divisional application of 1.6 (b) (filed: September 22, 2000);
(d) any US divisional patent applications covering the invention disclosed in the patent application 1.6 (b) above and the resulting patents;
(e) any US continuation-in-part application, and the resulting patents, which are directed to the invention disclosed in the patent applications described in sections 1.6 (b), (c) and (d) above;
(f) any Canadian and foreign patent applications, and the resulting patents, which are based on the invention disclosed in the patent applications described in sections 1.6(e) above; and
(g) any reissues, extensions and divisions of Canadian and foreign patents described in sections 1.6 (b), (c), (d), (e) and (f) above.
IPSCIO Record ID: 249713
â€¢ Any and all ANTIGENS expressed in Prostate Cancer
â€¢ Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
â€¢ Any and all Antigens expressed in Lung Cancer
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
IPSCIO Record ID: 110461
Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.
IPSCIO Record ID: 279375
IPSCIO Record ID: 212650
â€œLicensed Productâ€ shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.
Patents Claiming Priority to Patent Application Serial No. 08/276,358
IPSCIO Record ID: 28485
Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine. By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.
IPSCIO Record ID: 248332
Immune Modulator shall mean Coleys proprietary immunomodulatory oligonucleotide whose confidential sequence has been identified by Licensor as CpG 7909.
Licensed Product shall mean a product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, coformulated with one or more Antigens in a single vial; syringe or other suitable container.
VaxImmuneâ„¢ is one member of Coleyâ€™s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke potent innate and adaptive immune responses of the bodyâ€™s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmuneâ„¢ vaccine adjuvants are suitable for use in both prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers.
VaxImmune is known as a vaccine adjuvant, used in conjunction with a vaccine to improve immune responses and make the vaccine more effective.